- Home
- CRSP vs FG Comparison
CRSP vs FG Comparison
Compare CRSP & FG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- FG
- Stock Information
- Founded
- CRSP 2013
- FG 1959
- Country
- CRSP Switzerland
- FG United States
- Employees
- CRSP N/A
- FG N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- FG Life Insurance
- Sector
- CRSP Health Care
- FG Finance
- Exchange
- CRSP Nasdaq
- FG Nasdaq
- Market Cap
- CRSP 5.4B
- FG 4.3B
- IPO Year
- CRSP 2016
- FG N/A
- Fundamental
- Price
- CRSP $54.32
- FG $35.35
- Analyst Decision
- CRSP Buy
- FG Hold
- Analyst Count
- CRSP 16
- FG 3
- Target Price
- CRSP $72.27
- FG $44.33
- AVG Volume (30 Days)
- CRSP 2.9M
- FG 192.7K
- Earning Date
- CRSP 08-04-2025
- FG 08-06-2025
- Dividend Yield
- CRSP N/A
- FG 2.49%
- EPS Growth
- CRSP N/A
- FG N/A
- EPS
- CRSP N/A
- FG 2.52
- Revenue
- CRSP $38,050,000.00
- FG $5,309,000,000.00
- Revenue This Year
- CRSP $28.31
- FG N/A
- Revenue Next Year
- CRSP $268.05
- FG $22.50
- P/E Ratio
- CRSP N/A
- FG $14.02
- Revenue Growth
- CRSP N/A
- FG 1.86
- 52 Week Low
- CRSP $30.04
- FG $30.01
- 52 Week High
- CRSP $71.13
- FG $50.75
- Technical
- Relative Strength Index (RSI)
- CRSP 45.78
- FG 65.50
- Support Level
- CRSP $51.80
- FG $33.71
- Resistance Level
- CRSP $61.44
- FG $34.81
- Average True Range (ATR)
- CRSP 2.79
- FG 0.95
- MACD
- CRSP -0.79
- FG 0.05
- Stochastic Oscillator
- CRSP 26.14
- FG 73.29
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About FG F&G Annuities & Life Inc.
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.